Hypersomnia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HYP263 MIFTS: 44	Hypersomnia Categories: Mental diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Hypersomnia

MalaCards integrated aliases for Hypersomnia:

Name: Hypersomnia ⁵⁴ ⁷³

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Mental diseases

See all MalaCards categories (disease lists)

External Ids:

UMLS ⁷³ C0917799

Sources

Summaries for Hypersomnia

NINDS : ⁵⁴ Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary : Hypersomnia is related to idiopathic hypersomnia and recurrent hypersomnia, and has symptoms including excessive daytime somnolence, sleep disturbances and snoring. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways/superpathways are Phagosome and Cell adhesion molecules (CAMs). The drugs Armodafinil and Modafinil have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart.

Wikipedia : ⁷⁶ Hypersomnia, or hypersomnolence, is a neurological disorder of excessive time spent sleeping or... more...

Sources

Related Diseases for Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)

#	Related Disease	Score	Top Affiliating Genes
1	idiopathic hypersomnia	34.1	HCRT HLA-DQB1
2	recurrent hypersomnia	33.7	HCRT HLA-DQB1
3	kleine-levin hibernation syndrome	32.6	HCRT HLA-DQB1
4	narcolepsy	30.1	CHKB CPT1B HCRT HLA-DQB1 HLA-DRB1
5	neuromyelitis optica	29.9	HCRT HLA-DRB1
6	acute disseminated encephalomyelitis	29.8	HCRT HLA-DQB1 HLA-DRB1
7	whipple disease	29.8	HLA-DQB1 HLA-DRB1
8	idiopathic hypersomnia without long sleep time	12.3
9	idiopathic hypersomnia with long sleep time	12.2
10	dystonia, dopa-responsive, due to sepiapterin reductase deficiency	11.4
11	myotonic dystrophy 2	11.1
12	atypical depressive disorder	11.1
13	sleep apnea	10.4
14	depression	10.4
15	myotonic dystrophy	10.3
16	myotonia atrophica	10.2
17	bipolar disorder	10.1
18	brain injury	10.1
19	traumatic brain injury	10.1
20	prader-willi syndrome	10.1
21	major depressive disorder	10.1
22	mood disorder	10.1
23	limbic encephalitis with lgi1 antibodies	10.1	HLA-DQB1 HLA-DRB1
24	autoimmune polyglandular syndrome type 3	10.1	HLA-DQB1 HLA-DRB1
25	metal allergy	10.1	HLA-DQB1 HLA-DRB1
26	lichen planopilaris	10.1	HLA-DQB1 HLA-DRB1
27	type ii mixed cryoglobulinemia	10.1	HLA-DQB1 HLA-DRB1
28	beryllium disease	10.1	HLA-DQB1 HLA-DRB1
29	recurrent respiratory papillomatosis	10.1	HLA-DQB1 HLA-DRB1
30	chronic beryllium disease	10.1	HLA-DQB1 HLA-DRB1
31	lichen sclerosus	10.1	HLA-DQB1 HLA-DRB1
32	pityriasis rosea	10.1	HLA-DQB1 HLA-DRB1
33	pediatric multiple sclerosis	10.1	HLA-DQB1 HLA-DRB1
34	microscopic colitis	10.1	HLA-DQB1 HLA-DRB1
35	osteonecrosis of the jaw	10.1	HLA-DQB1 HLA-DRB1
36	idiopathic bronchiectasis	10.1	HLA-DQB1 HLA-DRB1
37	peanut allergy	10.1	HLA-DQB1 HLA-DRB1
38	oligoarticular juvenile idiopathic arthritis	10.1	HLA-DQB1 HLA-DRB1
39	endometritis	10.0	CHKB HLA-DQB1
40	glaucomatocyclitic crisis	10.0	HLA-DQB1 HLA-DRB1
41	geographic tongue	10.0	HLA-DQB1 HLA-DRB1
42	panuveitis	10.0	HLA-DQB1 HLA-DRB1
43	apnea, obstructive sleep	10.0
44	encephalitis	10.0
45	encephalopathy	10.0
46	ocular cicatricial pemphigoid	10.0	HLA-DQB1 HLA-DRB1
47	focal epithelial hyperplasia	10.0	HLA-DQB1 HLA-DRB1
48	paraneoplastic pemphigus	10.0	HLA-DQB1 HLA-DRB1
49	vogt-koyanagi-harada disease	10.0	HLA-DQB1 HLA-DRB1
50	rubella	10.0	HLA-DQB1 HLA-DRB1

Graphical network of the top 20 diseases related to Hypersomnia:

Sources

Symptoms & Phenotypes for Hypersomnia

UMLS symptoms related to Hypersomnia:

excessive daytime somnolence, sleep disturbances, snoring, sleeplessness, insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified, [d]sleep disturbances (& [hypersomnia] or [insomnia])

Sources

Drugs & Therapeutics for Hypersomnia

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 170)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Armodafinil

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

112111-43-0

Modafinil

Approved, Investigational

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

68693-11-8

4236

Dopamine

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

51-61-6, 62-31-7

681

Citalopram

Approved

Phase 4,Not Applicable

59729-33-8

2771

Bupropion

Approved

Phase 4

34841-39-9, 34911-55-2

444

Paroxetine

Approved, Investigational

Phase 4

61869-08-7

43815

Sertraline

Approved

Phase 4

79617-96-2

68617

Fluoxetine

Approved, Vet_approved

Phase 4

54910-89-3

3386

Selegiline

Approved, Investigational, Vet_approved

Phase 4

14611-51-9

26757 5195

Imidacloprid

Vet_approved

Phase 4

105827-78-9

86418

Wakefulness-Promoting Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Cytochrome P-450 CYP3A Inducers

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Central Nervous System Stimulants

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Peripheral Nervous System Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Neurotransmitter Agents

Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Cytochrome P-450 Enzyme Inhibitors

Phase 4,Phase 2

Serotonin Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Cholinergic Agents

Phase 4,Not Applicable

Neurotransmitter Uptake Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Serotonin Uptake Inhibitors

Phase 4,Not Applicable

Dopamine Uptake Inhibitors

Phase 4,Phase 2,Phase 1,Not Applicable

Antiparkinson Agents

Phase 4,Phase 2,Not Applicable

Antidepressive Agents

Phase 4,Phase 3,Phase 2,Not Applicable

Dopamine Agents

Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Antidepressive Agents, Second-Generation

Phase 4,Phase 3,Not Applicable

Parasympatholytics

Phase 4,Not Applicable

Psychotropic Drugs

Phase 4,Phase 3,Phase 2,Not Applicable

Cytochrome P-450 CYP2D6 Inhibitors

Phase 4

Autonomic Agents

Phase 4,Phase 2,Phase 1,Not Applicable

Muscarinic Antagonists

Phase 4,Not Applicable

Cholinergic Antagonists

Phase 4,Not Applicable

Immunologic Factors

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4,Phase 3,Phase 1,Phase 2

Vaccines

Phase 4,Phase 3,Phase 1,Phase 2

Dopamine agonists

Phase 4,Phase 2

Sympathomimetics

Phase 4,Phase 2,Phase 1

Monoamine Oxidase Inhibitors

Phase 4

Cardiotonic Agents

Phase 4

Protective Agents

Phase 4,Phase 1,Phase 2

Neuroprotective Agents

Phase 4,Phase 2

Anesthetics

Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1

Serotonin

Investigational, Nutraceutical

Phase 4,Phase 3,Phase 2,Not Applicable

50-67-9

5202

Morphine

Approved, Investigational

Phase 3

57-27-2

5288826

Caffeine

Approved

Phase 2, Phase 3,Not Applicable

58-08-2

2519

Histamine

Approved, Investigational

Phase 3,Phase 2

51-45-6, 75614-87-8

774

Norepinephrine

Approved

Phase 3

51-41-2

439260

Ixekizumab

Approved, Investigational

Phase 3,Phase 2

1143503-69-8

Lithium carbonate

Approved

Phase 3

554-13-2

leucovorin

Approved

Phase 3

58-05-9

6006 143

Methotrexate

Approved

Phase 3

59-05-2, 1959-05-2

126941

Interventional clinical trials:

(show top 50) (show all 177)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder	Completed	NCT01080807	Phase 4	Armodafinil;Matching Placebo
2	Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression	Completed	NCT00518986	Phase 4	armodafinil;placebo
3	Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance	Completed	NCT00711516	Phase 4	Armodafinil;Placebo
4	Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.	Completed	NCT00208715	Phase 4	Provigil
5	Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder	Completed	NCT01541475	Phase 4	Bupropion, Escitalopram;Escitalopram
6	An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue	Completed	NCT00678691	Phase 4	armodafinil;placebo
7	Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.	Completed	NCT01193335	Phase 4
8	Predictors of Antidepressant Response	Completed	NCT02178696	Phase 4	Celexa or other antidepressant as clinically indicated
9	Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists	Completed	NCT00443872	Phase 4	orally disintegrating selegiline (Zelapar)
10	A Trial Evaluating a 7-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants.	Completed	NCT01250756	Phase 4
11	MYnd Analytics Directed Therapy in Depression	Recruiting	NCT03328052	Phase 4
12	Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep Apnea	Terminated	NCT00730041	Phase 4
13	Palliative Morphine With or Without Concurrent Modafinil	Unknown status	NCT01766323	Phase 3	Modafinil;Placebo
14	Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder	Completed	NCT00758498	Phase 3	armodafinil;armodafinil;placebo
15	Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD	Completed	NCT00080288	Phase 3	Armodafinil 150 mg/day;Placebo
16	Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy	Completed	NCT00107796	Phase 3	Modafinil
17	PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome	Completed	NCT00107848	Phase 3	Modafinil
18	Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome	Completed	NCT00107809	Phase 3	Modafinil
19	Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy	Completed	NCT00078377	Phase 3	Armodafinil;Armodafinil;Placebo
20	"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"	Completed	NCT02348619	Phase 3	JZP-110
21	"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"	Completed	NCT02348606	Phase 3	JZP-110
22	"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"	Completed	NCT02348593	Phase 3	JZP-110
23	Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) Syndrome	Completed	NCT00079677	Phase 3	Armodafinil 150 mg/day;Placebo
24	Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)	Completed	NCT00078325	Phase 3	Armodafinil 250 mg/day;Armodafinil 150 mg/day;Placebo
25	Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive Sleepiness	Completed	NCT00214968	Phase 3	Modafinil
26	Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive Sleepiness	Completed	NCT00228553	Phase 3	Armodafinil 100 to 250 mg/day
27	Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome	Completed	NCT00228566	Phase 3	Armodafinil
28	"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"	Completed	NCT02348632	Phase 3	JZP-110
29	Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder	Completed	NCT00078312	Phase 3	CEP-10953 (Armodafinil)
30	Caffeine for Excessive Daytime Somnolence in Parkinson's Disease	Completed	NCT00459420	Phase 2, Phase 3	Caffeine 100-200 mg BID;placebo
31	A Trial of Negative Ion Generation Versus Light-Emitting Diode Phototherapy for Seasonal Affective Disorder (SAD)	Completed	NCT00809523	Phase 2, Phase 3
32	Efficacy and Safety of DHEA for Myotonic Dystrophy	Completed	NCT00167609	Phase 2, Phase 3	dehydroepiandrosterone 100 and 400 mg
33	Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGIL	Completed	NCT00236080	Phase 3	PROVIGIL 200 mg;Armodafinil 250 mg;Armodafinil 200 mg;Armodafinil 150 mg;Placebo
34	Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes Management	Completed	NCT00801892	Phase 3
35	Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.	Completed	NCT01638403	Phase 3	BF2.649;Vigil;palcebo
36	Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children	Completed	NCT00452452	Phase 3
37	Venlafaxine ER Long-Term Extension Study for Major Depressive Disorder (MDD)	Completed	NCT01485887	Phase 3	Venlafaxine ER
38	Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants	Completed	NCT00464945	Phase 3
39	Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)	Completed	NCT01441440	Phase 3	venlafaxine ER 75 mg/day (fixed dose);venlafaxine ER 75 mg/day to 225 mg/day (flexible dose);Placebo
40	A Study in Japanese Participants With Moderate-to-Severe Psoriasis	Completed	NCT01624233	Phase 3	80 mg ixekizumab
41	13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.	Completed	NCT01964716	Phase 3
42	Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.	Completed	NCT00366340	Phase 3
43	Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.	Completed	NCT00743652	Phase 3
44	Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants	Completed	NCT00384059	Phase 3
45	This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296	Completed	NCT01575561	Phase 3	Lurasidone
46	A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment	Completed	NCT02634801	Phase 3	Fumaric Acid Esters;Methotrexate;Ixekizumab
47	Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex	Completed	NCT01358357	Phase 3	Lurasidone;Placebo
48	Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants	Completed	NCT00366899	Phase 3
49	Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years	Completed	NCT00761631	Phase 3
50	Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia	Completed	NCT00856973	Phase 3	eszopiclone;eszopiclone;Placebo

Search NIH Clinical Center for Hypersomnia

Sources

Genetic Tests for Hypersomnia

Sources

Anatomical Context for Hypersomnia

MalaCards organs/tissues related to Hypersomnia:

⁴¹

Brain, Testes, Heart, Hypothalamus, Eye, B Cells, Tongue

Sources

Publications for Hypersomnia

Articles related to Hypersomnia:

(show top 50) (show all 383)

#	Title	Authors	Year
1	Update on treatment for idiopathic hypersomnia. ( 29250981 )	Evangelista E....Dauvilliers Y.	2018
2	Insomnia and hypersomnia in major depressive episode: Prevalence, sociodemographic characteristics and psychiatric comorbidity in a population-based study. ( 28972930 )	Geoffroy P.A....Peyre H.	2018
3	A case report of hypersomnia in tetrasomy X improved with medical therapy. ( 29744081 )	Jayaraman D....Hasbani D.M.	2018
4	Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors. ( 29116485 )	Khan R.B....Mandrell B.N.	2018
5	Alternative diagnostic criteria for idiopathic hypersomnia: A 32-hour protocol. ( 29323727 )	Evangelista E....Dauvilliers Y.	2018
6	Idiopathic Hypersomnia Patients Revealed Longer Circadian Period Length in Peripheral Skin Fibroblasts. ( 29930532 )	Materna L....Young P.	2018
7	Hypersomnia due to injury of the lower ventral ascending reticular activating system in a patient with intraventricular hemorrhage. ( 29966809 )	Jang S.H....Kwon Y.H.	2018
8	Associations Between Neuropsychological, Neurobehavioral and Emotional Functioning and Either Narcolepsy or Idiopathic Hypersomnia in Children and Adolescents. ( 29609710 )		2018
9	Nocturnal sleep architecture in idiopathic hypersomnia: a systematic review and meta-analysis. ( 29680423 )		2018
10	Hypothalamic relapse of a cardiac large B-cell lymphoma presenting with memory loss, confabulation, alexia-agraphia, apathy, hypersomnia, appetite disturbances and diabetes insipidus. ( 30150329 )	Ospina-Garc?a N...Preti HA	2018
11	Modafinil: its discovery, the early European and North American experience in the treatment of narcolepsy and idiopathic hypersomnia, and its subsequent use in other medical conditions. ( 30174215 )	Billiard M...Broughton R	2018
12	Hypersomnia. ( 30228690 )	Bollu PC...Sahota P	2018
13	A variant at 9q34.11 is associated with HLA-DQB1*06:02 negative essential hypersomnia. ( 30266950 )	Miyagawa T...Tokunaga K	2018
14	Mononucleosis: A Possible Cause of Idiopathic Hypersomnia. ( 30429823 )	Sforza E...Roche F	2018
15	Hypersomnia as an isolated symptom of neuromyelitis optica. ( 30517996 )	El Otmani H...Rafai MA	2018
16	A Case of Recurrent Hypersomnia With Autonomic Dysfunction. ( 28633719 )	Mahmoudi M....Kothare S.V.	2017
17	[18F]Fludeoxyglucose-Positron Emission Tomography Evidence for Cerebral Hypermetabolism in the Awake State in Narcolepsy and Idiopathic Hypersomnia. ( 28775709 )	Dauvilliers Y....Peigneux P.	2017
18	Hypersomnia: Evaluation, Treatment, and Social and Economic Aspects. ( 28159097 )	Saini P....Rye D.B.	2017
19	Hypersomnolence, Hypersomnia, and Mood Disorders. ( 28243864 )	Barateau L....Dauvilliers Y.	2017
20	Brain MRI findings in patients with idiopathic hypersomnia. ( 28376374 )	Trotti L.M....Bliwise D.L.	2017
21	Recurrent Hypersomnia and Autonomic Dysregulation in Posttraumatic Stress Disorder. ( 29117891 )	Gupta M.A.	2017
22	Hypersomnia hiding a bipolar disorder. ( 28687972 )	Martino I....Labate A.	2017
23	Test-Retest Reliability of Two Consecutive Mean Sleep Latency Tests in Patients with Hypersomnia. ( 29249902 )	Kwon Y....Mahowald M.W.	2017
24	Efficacy, Safety, and Tolerability of Armodafinil Therapy for Hypersomnia Associated with Dementia with Lewy Bodies: A Pilot Study. ( 28448998 )	Lapid M.I....Boeve B.F.	2017
25	Hypersomnia in Neurodegenerative Diseases. ( 28778241 )	Bhat S....Chokroverty S.	2017
26	Life-time history of insomnia and hypersomnia symptoms as correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use treatment in the United States from 1991 to 1994. ( 28127809 )	Dolsen M.R....Harvey A.G.	2017
27	Val158Met polymorphism in the COMT gene is associated with hypersomnia and mental health-related quality of life in a Colombian sample. ( 28235603 )		2017
28	Neurobiological Basis of Hypersomnia. ( 28778226 )		2017
29	Narcolepsy type 1 and hypersomnia associated with a psychiatric disorder show different slow wave activity dynamics. ( 28691719 )		2017
30	Usefulness of brain SPECT imaging in the study of recurrent hypersomnia: Kleine-Levin syndrome. ( 28869046 )		2017
31	Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic. ( 28302408 )		2017
32	A case of hypersomnia due to bilateral thalamic stroke. ( 29026583 )		2017
33	Hypersomnia: an overlooked, but not overestimated, sleep disturbance in bipolar disorder. ( 28235881 )		2017
34	Depression and Hypersomnia: A Complex Association. ( 28778237 )		2017
35	Idiopathic Hypersomnia. ( 28778232 )		2017
36	Case Report of a Patient With Idiopathic Hypersomnia and a Family History of Malignant Hyperthermia Undergoing General Anesthesia: An Overview of the Anesthetic Considerations. ( 28328583 )		2017
37	Hypersomnia and cognitive impairment in a patient with bipolar disorder - a case report. ( 28866718 )	Szauli?ska K...Wichniak A	2017
38	Improving the Comprehensive Care of Patients With Hypersomnia Disorders: A Commentary on "Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey Study". ( 27849365 )	Zhou ES	2017
39	French consensus. Management of patients with hypersomnia: Which strategy? ( 27865546 )	Lopez R...Dauvilliers Y	2017
40	Effectiveness of ramelteon for residual sleep disturbances (hypersomnia) in a patient with premenstrual dysphoric disorder. ( 27868343 )	Yamada K	2017
41	Hypersomnia due to injury of the ventral ascending reticular activating system following cerebellar herniation: A case report. ( 28072702 )	Jang SH...Kwon HG	2017
42	Diffusion tensor imaging tractography and MRI perfusion in post traumatic brain injury hypersomnia. ( 28522105 )	Puligheddu M...Peltz MT	2017
43	Altered Regional Cerebral Blood Flow in Idiopathic Hypersomnia. ( 28958044 )	Boucetta S...Dang-Vu TT	2017
44	Urine Toxicology in Adults Evaluated for a Central Hypersomnia and How the Results Modify the Physician's Diagnosis. ( 27568897 )	Kosky C.A....Williams A.J.	2016
45	Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review. ( 26847972 )	Leu-Semenescu S....Arnulf I.	2016
46	Menstruation-Related Hypersomnia Treated with Hormonal Contraception: Case Report and Review of Literature. ( 26932284 )	Suau G.M....Romaguera J.	2016
47	Diurnal and nocturnal cardiovascular variability and heart rate arousal response in idiopathic hypersomnia. ( 27810179 )	Sforza E....Pichot V.	2016
48	Injury of the Ascending Reticular Activating System in Patients With Fatigue and Hypersomnia Following Mild Traumatic Brain Injury: Two Case Reports. ( 26871783 )	Jang S.H....Kwon H.G.	2016
49	French consensus. Idiopathic hypersomnia: Investigations and follow-up. ( 27838089 )	Leu-Semenescu S....Dauvilliers Y.	2016
50	Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey Study. ( 26788889 )	Neikrug A.B....Ong J.C.	2016

Sources

Genes for Hypersomnia

Genes related to Hypersomnia (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	HLA-DQB1	Major Histocompatibility Complex, Class II, DQ Beta 1	Protein Coding	17.34	GeneCards inferred via : Publications (show sections)
2	HLA-DRB1	Major Histocompatibility Complex, Class II, DR Beta 1	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
3	HCRT	Hypocretin Neuropeptide Precursor	Protein Coding	17.09	GeneCards inferred via : Publications (show sections)
4	CPT1B	Carnitine Palmitoyltransferase 1B	Protein Coding	16.88	GeneCards inferred via : Publications (show sections)
5	CHKB	Choline Kinase Beta	Protein Coding	16.88	GeneCards inferred via : Publications (show sections)

Sources

Variations for Hypersomnia

Sources

Expression for Hypersomnia

Search GEO for disease gene expression data for Hypersomnia.

Sources

Pathways for Hypersomnia

Pathways related to Hypersomnia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Phagosome ³⁷	11.66	HLA-DQB1 HLA-DRB1
2	Cell adhesion molecules (CAMs) ³⁷	11.59	HLA-DQB1 HLA-DRB1
3	S-1P Stimulated Signaling ⁶⁴	11.44	HLA-DQB1 HLA-DRB1
4	Translocation of ZAP-70 to Immunological synapse ⁶⁶ Show member pathways Generation of second messenger molecules ⁶⁶ PD-1 signaling ⁶⁶ Phosphorylation of CD3 and TCR zeta chains ⁶⁶	11.44	HLA-DQB1 HLA-DRB1
5	MHC class II antigen presentation ⁶⁶	11.38	HLA-DQB1 HLA-DRB1
6	Hematopoietic cell lineage ³⁷	11.31	HLA-DQB1 HLA-DRB1
7	Rheumatoid arthritis ³⁷	11.21	HLA-DQB1 HLA-DRB1
8	CTLA4 Signaling ⁶⁴	11.01	HLA-DQB1 HLA-DRB1
9	Staphylococcus aureus infection ³⁷	10.7	HLA-DQB1 HLA-DRB1
10	Mitochondrial LC-Fatty Acid Beta-Oxidation ¹ Show member pathways Fatty Acid Beta Oxidation ¹ fatty acid beta-oxidation (unsaturated, odd number) ¹	10.35	CHKB CPT1B

Sources

GO Terms for Hypersomnia

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	trans-Golgi network membrane	GO:0032588	9.4	HLA-DQB1 HLA-DRB1
2	endocytic vesicle membrane	GO:0030666	9.37	HLA-DQB1 HLA-DRB1
3	ER to Golgi transport vesicle membrane	GO:0012507	9.32	HLA-DQB1 HLA-DRB1
4	transport vesicle membrane	GO:0030658	9.26	HLA-DQB1 HLA-DRB1
5	clathrin-coated endocytic vesicle membrane	GO:0030669	9.16	HLA-DQB1 HLA-DRB1
6	integral component of lumenal side of endoplasmic reticulum membrane	GO:0071556	8.96	HLA-DQB1 HLA-DRB1
7	MHC class II protein complex	GO:0042613	8.62	HLA-DQB1 HLA-DRB1

Biological processes related to Hypersomnia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	T cell receptor signaling pathway	GO:0050852	9.4	HLA-DQB1 HLA-DRB1
2	antigen processing and presentation of exogenous peptide antigen via MHC class II	GO:0019886	9.37	HLA-DQB1 HLA-DRB1
3	interferon-gamma-mediated signaling pathway	GO:0060333	9.32	HLA-DQB1 HLA-DRB1
4	antigen processing and presentation	GO:0019882	9.26	HLA-DQB1 HLA-DRB1
5	antigen processing and presentation of peptide or polysaccharide antigen via MHC class II	GO:0002504	9.16	HLA-DQB1 HLA-DRB1
6	humoral immune response mediated by circulating immunoglobulin	GO:0002455	8.96	HLA-DQB1 HLA-DRB1
7	immunoglobulin production involved in immunoglobulin mediated immune response	GO:0002381	8.62	HLA-DQB1 HLA-DRB1

Molecular functions related to Hypersomnia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	peptide antigen binding	GO:0042605	8.96	HLA-DQB1 HLA-DRB1
2	MHC class II receptor activity	GO:0032395	8.62	HLA-DQB1 HLA-DRB1

Sources

Sources for Hypersomnia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia